{"source_content":"2020年07月血制品行业批签发跟踪证券研究报告2020年08月医药生物投资评级推荐维持分析师:常启辉执业资格证：S0020517090001电话:021-51097188E-MAIL:changqihui@gyzq.com.cn联系人：刘巧电话：021-51097188E-MAIL：liuqiao@gyzq.com.cn联系人：汤芬芬电话：021-51097188E-MAIL：tangfenfen@gyzq.com.cn联系人:刘慧敏电话:021-51097188E-MAIL:liuhuimin@gyzq.com.cn请务必阅读正文之后的免责条款部分【国元医药】血液制品-月度行业报告2投资摘要：•7月血制品总计实现批签发670.76万瓶，同比下降14.71%，环比下降12.39%。2020年1-7月累计批签发5680万瓶，同比增长34.36%，疫情以来，受供应端和需求端的不同程度影响，血制品批签发波动较大。•白蛋白本月批签发382.58万瓶，同比下降3.09%，其中国产白蛋白占比达51.02%，批签量反超进口，天坛生物在国产白蛋白中贡献最大（14.04%）；静丙本月批签发100.76万瓶，同比下降23.29%，环比增长2.49%，批签量在疫情后逐步恢复稳定，贡献较大的公司包括天坛生物（29.18%）与上海莱士（27.58%）。•血浆供应紧张，血制品或将进入提价周期。据输血研究所相关数据显示，2020H1国内血浆采集量较去年同期下降22%，同比减少近1000吨；海外供浆同样受到影响，据美国血浆采集中心的跟踪报告显示，与去年同期相比，2020年4-6月献浆人数下降49%。在全球疫情尚未得到全面控制下，预计血浆供应将继续维持吃紧状态，血制品行业或将进入提价周期，政策鼓励或放开新增采浆站，有待跟踪。•海外巨头受疫情影响，或将影响明年供应。海外血制品巨头如CSL表示由于疫情的影响公司上半年采浆量有所下跌，但是预计库存能够保证今年的供应，今年1-7月进口白蛋白批签量占达62.90%，采浆量的下滑或将影响海外公司明年的血制品供应。•投资评级：血制品行业景气度较高，我们维持推荐评级，建议关注天坛生物、华兰生物等血液制品行业龙头企业。•风险提示：血浆供应不及预期、行业监管风险、生产安全性风险、政策风险。资料来源：中检院及各地方所，国元证券研究中心注：本文采用数据均进行标化。请务必阅读正文之后的免责条款部分【国元医药】血液制品批签发数据跟踪by2020073本月批签发重点品种及主要观点：本月血制品总计实现批签发670.76万瓶，同比下降14.71%，环比下降12.39%，整体批签量稳定，环比下滑主要由于狂免批签量的收缩。白蛋白批签发382.58万瓶，同比下降3.09%，环比下降8.05%，其中进口白蛋白占48.98%，同比下降8.39%；国产白蛋白批占51.02%，同比增长2.06%，国外疫情蔓延，采浆量下滑，预计在华供货节奏有所调整，国产白蛋白批签量在本月反超进口，白蛋白有望进入提价周期。静丙批签发100.76万瓶，同比下降23.29%，环比增长2.49%，预计静丙库存仍在消化中，批签发正在逐步恢复正常。其他品种：本月狂免批签发107.96万、破免31.12万、乙免8.46万、纤原7.82万、八因子20.97万、PCC8.64万。本月重点企业批签发情况：天坛生物本月批签发111.48万瓶，包括白蛋白53.72万、静丙29.40万、狂免12.10万、破免7.80万、乙免8.46万，白蛋白批签发增幅较大，为今年来单月最高；狂免、破免、乙免恢复批签发；静丙批签发稳定。华兰生物本月批签发36.16万瓶，包括白蛋白16.58万、静丙8.93万、破免6.18万、八因子2.91万、PCC1.56万。博雅生物本月批签发24.74万瓶，包括白蛋白9.34万、静丙2.52万、狂免10.64万、纤原2.23万，白蛋白批签量保持稳定，静丙有所下滑。上海莱士本月批签发84.09万瓶，包括白蛋白10.74万、静丙27.79万、狂免37.24万、八因子7.50万、纤原0.81万，静丙批签量，狂免重新开始获得批签发。泰邦生物本月批签发55.73万瓶，包括白蛋白35.59万、静丙3.47万、八因子6.48万、PCC7.08万、纤原3.10万。双林生物本月批签发20.50万瓶，包括白蛋白3.40万、静丙1.75万、狂免15.35万。资料来源：中检院及各地方所，国元证券研究中心请务必阅读正文之后的免责条款部分重点品种跟踪4资料来源：中检院及各地方所，国元证券研究中心请务必阅读正文之后的免责条款部分重点品种跟踪5白蛋白资料来源：中检院及各地方所，国元证券研究中心静丙肌丙本月白蛋白批签发382.58万瓶，同比下降3.09%。进口白蛋白批签发187.38万，占48.98%，同比下降8.39%，主要来自CSL（15.69%）、Octapharma（13.19%）、Grifols（9.92%）、Baxalta（9.54%）。国产白蛋白批签发195.21万，同比增长2.06%，批签量反超进口，主要来自天坛生物（14.04%）、泰邦生物（9.30%）、远大蜀阳（5.30%）、华兰生物（4.33%）。本月静丙批签发100.76万瓶，同比下降23.29%，主要来自天坛（29.18%）、上海莱士（27.58%）、双林（13.54%）、远大蜀阳（12.04%）、华兰生物（8.87%）。静丙批签量在疫情后逐步恢复稳定。本月肌丙批签发2.42万瓶，全部来自博晖创新。请务必阅读正文之后的免责条款部分重点品种跟踪6资料来源：中检院及各地方所，国元证券研究中心纤维蛋白原凝血酶原复合物凝血因子VIII本月纤原批签发7.82万瓶，同比下降36.49%，主要来自泰邦（39.70%）、博雅生物（28.55%）、卫光生物（13.68%）、上海莱士（10.40%）。本月八因子批签发20.97万瓶，同比增长20.78%，来自上海莱士（35.75%）、泰邦生物（30.91%）、绿十字（19.47%）、华兰生物（13.87%）。本月PCC批签发8.64万瓶，同比增长105.04%，来自泰邦生物（81.90%）、华兰生物（18.10%）。请务必阅读正文之后的免责条款部分重点品种跟踪7资料来源：中检院及各地方所，国元证券研究中心狂免破免乙免本月狂免批签发107.96万瓶，主要来自上海莱士（34.50%）、双林生物（19.36%）、卫光生物、天坛生物（14.83%）、远大蜀阳（11.21%）。狂免本月由于泰邦等几家企业没有批签发，环比有所下降。本月破免批签发31.12万瓶，来自远大蜀阳（40.84%）、天坛生物（25.06%）、华兰生物（19.87%）、双林生物（14.23%）。本月乙免批签发8.46万瓶，主要来自远大蜀阳（37.22%）、天坛生物（20.41%）、南岳生物（13.25%）、华兰生物（12.72%）。请务必阅读正文之后的免责条款部分重点公司跟踪8天坛生物本月批签发111.48万瓶，同比增长2.66%，包括白蛋白53.72万、静丙29.40万、狂免12.10万、破免7.80万、乙免8.46万，其余品种未有批签发。截止7月公司已完成去年整体批签发的59.99%。公司本月白蛋白批签发增幅较大，为今年来单月最高；狂免、破免、乙免恢复批签发；静丙批签发稳定。本月批签发24.74万瓶，包括白蛋白9.34万、静丙2.52万、狂免10.64万、纤原2.23万，其余品种未有批签发。截止7月公司已完成去年整体批签发的74.69%。公司白蛋白批签量相对稳定；静丙本月有所下滑。本月批签发36.16万瓶，包括白蛋白16.58万、静丙8.93万、破免6.18万、八因子2.91万、PCC1.56万，其余品种未有批签发。截止7月公司已完成去年整体批签发的54.81%。资料来源：中检院及各地方所，国元证券研究中心华兰生物博雅生物请务必阅读正文之后的免责条款部分重点公司跟踪9上海莱士本月批签发84.09万瓶，包括白蛋白10.74万、静丙27.79万、狂免37.24万、八因子7.50万、纤原0.81万。截止7月公司已完成去年整体批签发的66.42%。整体批签量增长归因于静丙批签量的恢复与狂免重新开始获得批签发。本月批签发20.50万瓶，包括白蛋白3.40万、静丙1.75万、狂免15.35万，其余品种未有批签发。截止7月公司已完成去年整体批签发的56.67%。本月批签发55.73万瓶，包括白蛋白35.59万、静丙3.47万、八因子6.48万、PCC7.08万、纤原3.10万，其余品种未有批签发。截止7月公司已完成去年整体批签发的70.96%。资料来源：中检院及各地方所，国元证券研究中心泰邦生物双林生物请务必阅读正文之后的免责条款部分10分析师声明作者具有中国证券业协会授予的证券投资咨询执业资格或相当的专业胜任能力，以勤勉的职业态度，独立、客观地出具本报告。本人承诺报告所采用的数据均来自合规渠道，分析逻辑基于作者的职业操守和专业能力，本报告清晰准确地反映了本人的研究观点并通过合理判断得出结论，结论不受任何第三方的授意、影响。证券投资咨询业务的说明根据中国证监会颁发的《经营证券业务许可证》（Z23834000),国元证券股份有限公司具备中国证监会核准的证券投资咨询业务资格。证券投资咨询业务是指取得监管部门颁发的相关资格的机构及其咨询人员为证券投资者或客户提供证券投资的相关信息、分析、预测或建议，并直接或间接收取服务费用的活动。证券研究报告是证券投资咨询业务的一种基本形式，指证券公司、证券投资咨询机构对证券及证券相关产品的价值、市场走势或者相关影响因素进行分析，形成证券估值、投资评级等投资分析意见，制作证券研究报告，并向客户发布的行为。（1）公司评级定义（2）行业评级定义买入预计未来6个月内，股价涨跌幅优于上证指数20%以上推荐预计未来6个月内，行业指数表现优于市场指数10%以上中性预计未来6个月内，行业指数表现介于市场指数±10%之间回避预计未来6个月内，行业指数表现劣于市场指数10%以上增持预计未来6个月内，股价涨跌幅优于上证指数5-20%之间持有预计未来6个月内，股价涨跌幅介于上证指数±5%之间卖出预计未来6个月内，股价涨跌幅劣于上证指数5%以上请务必阅读正文之后的免责条款部分11一般性声明本报告仅供国元证券股份有限公司（以下简称“本公司”）的客户使用。本公司不会因接收人收到本报告而视其为客户。若国元证券以外的金融机构或任何第三方机构发送本报告，则由该金融机构或第三方机构独自为此发送行为负责。本报告不构成国元证券向发送本报告的金融机构或第三方机构之客户提供的投资建议，国元证券及其员工亦不为上述金融机构或第三方机构之客户因使用本报告或报告载述的内容引起的直接或连带损失承担任何责任。本报告是基于本公司认为可靠的已公开信息，但本公司不保证该等信息的准确性或完整性。本报告所载的信息、资料、分析工具、意见及推测只提供给客户作参考之用，并非作为或被视为出告或购买证券或其他投资标的的投资建议或要约邀请。本报告所指的证券或投资标的的价格、价值及投资收入可能会波动。在不同时期，本公司可发出与本报告所载资料、意见及推测不一致的报告。本公司建议客户应考虑本报告的任何意见或建议是否符合其特定状况，以及（若有必要）咨询独立投资顾问。在法律许可的情况下，本公司及其所属关联机构可能会持有本报告中所提到的公司所发行的证券头寸并进行交易，还可能为这些公司提供或争取投资银行业务服务或其他服务。免责条款本报告是为特定客户和其他专业人士提供的参考资料。文中所有内容均代表个人观点。本公司力求报告内容的准确可靠，但并不对报告内容及所引用资料的准确性和完整性作出任何承诺和保证。本公司不会承担因使用木报告而产生的法律责任。本报告版权归国元证券所有，未经授权不得复印、转发或向特定读者群以外的人士传阅，如需引用或转载本报告，务必与本公司研宄中心联系。网址:www.gyzq.com.cn","data":[{"id":"1","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"7月血制品总计实现批签发670.76万瓶","content_offset":["303","323"],"indicators":[{"indicator_name":"批签发量","indicator_value":["670.76万瓶","315","323"],"indicator_element":{"时间":["7月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"2","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降14.71%","content_offset":["324","334"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降14.71%","326","334"],"indicator_element":{"时间":["7月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"3","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"环比下降12.39%","content_offset":["335","345"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["下降12.39%","337","345"],"indicator_element":{"时间":["7月","303","305"],"行业":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"4","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"2020年1-7月累计批签发5680万瓶","content_offset":["346","366"],"indicators":[{"indicator_name":"批签发量","indicator_value":["5680万瓶","360","366"],"indicator_element":{"时间":["2020年1-7月","346","355"],"产品":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"5","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比增长34.36%","content_offset":["367","377"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长34.36%","369","377"],"indicator_element":{"时间":["2020年1-7月","346","355"],"产品":["血制品","305","308"]},"indicator_supplement":{"属性":""}}]},{"id":"6","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"白蛋白本月批签发382.58万瓶","content_offset":["411","427"],"indicators":[{"indicator_name":"批签发量","indicator_value":["382.58万瓶","419","427"],"indicator_element":{"时间":["本月","414","416"],"产品":["白蛋白","411","414"]},"indicator_supplement":{"属性":""}}]},{"id":"7","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降3.09%","content_offset":["428","437"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3.09%","430","437"],"indicator_element":{"时间":["本月","414","416"],"产品":["白蛋白","411","414"]},"indicator_supplement":{"属性":""}}]},{"id":"8","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"其中国产白蛋白占比达51.02%","content_offset":["438","454"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["51.02%","448","454"],"indicator_element":{"时间":["本月","414","416"],"产品":["白蛋白","442","445"],"渠道":["国产","440","442"]},"indicator_supplement":{"属性":""}}]},{"id":"9","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"静丙本月批签发100.76万瓶","content_offset":["487","502"],"indicators":[{"indicator_name":"批签发量","indicator_value":["100.76万瓶","494","502"],"indicator_element":{"时间":["本月","489","491"],"产品":["静丙","487","489"]},"indicator_supplement":{"属性":""}}]},{"id":"10","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降23.29%","content_offset":["503","513"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降23.29%","505","513"],"indicator_element":{"时间":["本月","414","416"],"产品":["静丙","487","489"]},"indicator_supplement":{"属性":""}}]},{"id":"11","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"环比增长2.49%","content_offset":["514","523"],"indicators":[{"indicator_name":"批签发量环比","indicator_value":["增长2.49%","516","523"],"indicator_element":{"时间":["本月","414","416"],"产品":["静丙","487","489"]},"indicator_supplement":{"属性":""}}]},{"id":"12","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"2020H1国内血浆采集量较去年同期下降22%","content_offset":["606","629"],"indicators":[{"indicator_name":"采浆量","indicator_value":["下降22%","624","629"],"indicator_element":{"时间":["2020H1","606","612"],"产品":["血浆","614","616"],"区域":["国内","612","614"]},"indicator_supplement":{"属性":""}}]},{"id":"13","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比减少近1000吨","content_offset":["630","640"],"indicators":[{"indicator_name":"采浆量同比","indicator_value":["减少近1000吨","632","640"],"indicator_element":{"时间":["2020H1","606","612"],"产品":["血浆","574","576"],"区域":["国内","612","614"]},"indicator_supplement":{"属性":""}}]},{"id":"14","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"今年1-7月进口白蛋白批签量占达62.90%","content_offset":["828","850"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["62.90%","844","850"],"indicator_element":{"时间":["今年1-7月","828","834"],"渠道":["进口","834","836"]},"indicator_supplement":{"属性":""}}]},{"id":"15","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月白蛋白批签发382.58万瓶","content_offset":["1954","1970"],"indicators":[{"indicator_name":"批签发量","indicator_value":["382.58万瓶","1962","1970"],"indicator_element":{"时间":["本月","1954","1956"],"产品":["白蛋白","1956","1959"]},"indicator_supplement":{"属性":""}}]},{"id":"16","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降3.09%","content_offset":["428","437"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降3.09%","430","437"],"indicator_element":{"时间":["本月","414","416"],"产品":["白蛋白","411","414"]},"indicator_supplement":{"属性":""}}]},{"id":"17","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"进口白蛋白批签发187.38万","content_offset":["1982","1997"],"indicators":[{"indicator_name":"批签发量","indicator_value":["187.38万","1990","1997"],"indicator_element":{"时间":["本月","1954","1956"],"产品":["白蛋白","1984","1987"],"渠道":["进口","1982","1984"]},"indicator_supplement":{"属性":""}}]},{"id":"18","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"占48.98%","content_offset":["1165","1172"],"indicators":[{"indicator_name":"批签发量占比","indicator_value":["48.98%","1166","1172"],"indicator_element":{"时间":["本月","1242","1244"],"产品":["白蛋白","1123","1126"],"渠道":["进口","1160","1162"]},"indicator_supplement":{"属性":""}}]},{"id":"19","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降8.39%","content_offset":["1173","1182"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降8.39%","1175","1182"],"indicator_element":{"时间":["本月","1242","1244"],"产品":["白蛋白","1123","1126"],"渠道":["进口","1160","1162"]},"indicator_supplement":{"属性":""}}]},{"id":"20","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月静丙批签发100.76万瓶","content_offset":["2170","2185"],"indicators":[{"indicator_name":"批签发量","indicator_value":["100.76万瓶","2177","2185"],"indicator_element":{"时间":["本月","2170","2172"],"产品":["静丙","2172","2174"]},"indicator_supplement":{"属性":""}}]},{"id":"21","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降23.29%","content_offset":["503","513"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降23.29%","505","513"],"indicator_element":{"时间":["本月","414","416"],"产品":["静丙","487","489"]},"indicator_supplement":{"属性":""}}]},{"id":"22","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月肌丙批签发2.42万瓶","content_offset":["2279","2292"],"indicators":[{"indicator_name":"批签发量","indicator_value":["2.42万瓶","2286","2292"],"indicator_element":{"时间":["本月","2279","2281"],"产品":["肌丙","2281","2283"]},"indicator_supplement":{"属性":""}}]},{"id":"23","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月纤原批签发7.82万瓶","content_offset":["2368","2381"],"indicators":[{"indicator_name":"批签发量","indicator_value":["7.82万瓶","2375","2381"],"indicator_element":{"时间":["本月","2368","2370"],"产品":["纤原","2370","2372"]},"indicator_supplement":{"属性":""}}]},{"id":"24","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比下降36.49%","content_offset":["2382","2392"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["下降36.49%","2384","2392"],"indicator_element":{"时间":["本月","2368","2370"],"产品":["纤原","2370","2372"]},"indicator_supplement":{"属性":""}}]},{"id":"25","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月八因子批签发20.97万瓶","content_offset":["2448","2463"],"indicators":[{"indicator_name":"批签发量","indicator_value":["20.97万瓶","2456","2463"],"indicator_element":{"时间":["本月","2448","2450"],"产品":["八因子","2450","2453"]},"indicator_supplement":{"属性":""}}]},{"id":"26","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比增长20.78%","content_offset":["2464","2474"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长20.78%","2466","2474"],"indicator_element":{"时间":["本月","2368","2370"],"产品":["八因子","2450","2453"]},"indicator_supplement":{"属性":""}}]},{"id":"27","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月PCC批签发8.64万瓶","content_offset":["2529","2543"],"indicators":[{"indicator_name":"批签发量","indicator_value":["8.64万瓶","2537","2543"],"indicator_element":{"时间":["本月","2529","2531"],"产品":["PCC","2531","2534"]},"indicator_supplement":{"属性":""}}]},{"id":"28","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"同比增长105.04%","content_offset":["2544","2555"],"indicators":[{"indicator_name":"批签发量同比","indicator_value":["增长105.04%","2546","2555"],"indicator_element":{"时间":["本月","2448","2450"],"产品":["PCC","2531","2534"]},"indicator_supplement":{"属性":""}}]},{"id":"29","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月狂免批签发107.96万瓶","content_offset":["2636","2651"],"indicators":[{"indicator_name":"批签发量","indicator_value":["107.96万瓶","2643","2651"],"indicator_element":{"时间":["本月","2636","2638"],"产品":["狂免","2638","2640"]},"indicator_supplement":{"属性":""}}]},{"id":"30","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月破免批签发31.12万瓶","content_offset":["2741","2755"],"indicators":[{"indicator_name":"批签发量","indicator_value":["31.12万瓶","2748","2755"],"indicator_element":{"时间":["本月","2741","2743"],"产品":["破免","2743","2745"]},"indicator_supplement":{"属性":""}}]},{"id":"31","source_document":"2020年07月血制品行业批签发跟踪.pdf","content":"本月乙免批签发8.46万瓶","content_offset":["2811","2824"],"indicators":[{"indicator_name":"批签发量","indicator_value":["8.46万瓶","2818","2824"],"indicator_element":{"时间":["本月","2811","2813"],"产品":["乙免","2813","2815"]},"indicator_supplement":{"属性":""}}]}]}